Literature DB >> 18559497

Underexpression of RhoH in Hairy Cell Leukemia.

Sylvie Galiègue-Zouitina1, Laure Delestré, Caroline Dupont, Xavier Troussard, Carl Simon Shelley.   

Abstract

The cause of hairy cell leukemia (HCL) is unknown. Current treatments seem effective only for a limited period of time. In addition, a significant proportion of patients remain refractive to all treatment options. These considerations indicate the need to develop alternative therapeutic strategies for HCL. Here, we report that HCL is characterized by underexpression of RhoH. In vitro reconstitution of RhoH expression inhibits the aberrant adhesion and transendothelial migration that drives disease pathogenesis. In an in vivo model of HCL, RhoH reconstitution limits malignant progression and protects against mortality. These findings provide the proof of principle that RhoH reconstitution represents a potential new approach to the treatment of HCL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559497     DOI: 10.1158/0008-5472.CAN-07-5661

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Crossing the endothelial barrier during metastasis.

Authors:  Nicolas Reymond; Bárbara Borda d'Água; Anne J Ridley
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

Review 2.  Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders.

Authors:  Anja Troeger; David A Williams
Journal:  Exp Cell Res       Date:  2013-07-11       Impact factor: 3.905

3.  Deletion of murine Rhoh leads to de-repression of Bcl-6 via decreased KAISO levels and accelerates a malignancy phenotype in a murine model of lymphoma.

Authors:  Hiroto Horiguchi; Haiming Xu; Beatrice Duvert; Felicia Ciuculescu; Qiuming Yao; Amit Sinha; Meaghan McGuinness; Chad Harris; Christian Brendel; Anja Troeger; Roberto Chiarle; David A Williams
Journal:  Small GTPases       Date:  2022-01

4.  Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy.

Authors:  Sylvie Galiègue-Zouitina; Qiangwei Fu; Céline Carton-Latreche; Nicolas Poret; Meyling Cheok; Frédéric Leprêtre; Martin Figeac; Bruno Quesnel; Hassiba El Bouazzati; Carl S Shelley
Journal:  EJHaem       Date:  2021-01-20

Review 5.  Rho GTPases in hematopoiesis and hemopathies.

Authors:  James C Mulloy; Jose A Cancelas; Marie-Dominique Filippi; Theodosia A Kalfa; Fukun Guo; Yi Zheng
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

6.  The haematopoietic GTPase RhoH modulates IL3 signalling through regulation of STAT activity and IL3 receptor expression.

Authors:  Mehtap S Gündogdu; He Liu; Daniela Metzdorf; Dagmar Hildebrand; Michael Aigner; Klaus Aktories; Klaus Heeg; Katharina F Kubatzky
Journal:  Mol Cancer       Date:  2010-08-25       Impact factor: 27.401

7.  A unique carboxyl-terminal insert domain in the hematopoietic-specific, GTPase-deficient Rho GTPase RhoH regulates post-translational processing.

Authors:  Anja Troeger; Hee-Don Chae; Mumine Senturk; Jenna Wood; David A Williams
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

Review 8.  RHO Family GTPases in the Biology of Lymphoma.

Authors:  Claudia Voena; Roberto Chiarle
Journal:  Cells       Date:  2019-06-26       Impact factor: 6.600

9.  The small GTPase RhoH is an atypical regulator of haematopoietic cells.

Authors:  Florian Fueller; Katharina F Kubatzky
Journal:  Cell Commun Signal       Date:  2008-09-29       Impact factor: 5.712

Review 10.  Rho GTPases, their post-translational modifications, disease-associated mutations and pharmacological inhibitors.

Authors:  Michael F Olson
Journal:  Small GTPases       Date:  2016-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.